𝔖 Bobbio Scriptorium

✦ LIBER ✦

Response to brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal

✍ Scribed by C. Leonardi

Book ID: 117940095
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 105 KB
Volume: 167
Category: Article
ISSN: 0007-0963
DOI: 10.1111/bjd.12027

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Brodalumab and ixekizumab, anti-interleu

Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal : ORIGINAL ARTICLE: Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181–9.ORIGINAL ARTICLE: Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190–9.

✍ Ph. I. Spuls; L. Hooft 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Clinical pharmacology of the anti-IL-17

Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: A randomized, dose-escalation, placebo-controlled study

✍ Osamu, Nemoto; Hirotaka, Nagashima; Koji, Sayama; Kenji, Takazawa 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 920 KB